Benzene Ring Nonionically Bonded Patents (Class 514/567)
  • Patent number: 11826328
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: November 28, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Kenneth Robert Phares, Hitesh Batra, Liang Guo
  • Patent number: 11820764
    Abstract: The present invention provides a novel compound of formula I, its derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for modulating GSK3 level (e.g., GSK3 (e.g., GSK3a/GSK3b or GSK3P) or CK1) hence, activity.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: November 21, 2023
    Assignee: National Institute of Immunology
    Inventors: Sarika Gupta, Ibrar Ahmed Siddiqui, Aishwarya Nilakhe, Prabhat Upadhyay
  • Patent number: 11813235
    Abstract: Disclosed are methods for using guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof, to reduce the virulence of a bacterial pathogen. When treating a patient, the method generally involves administering to the patient a therapeutically effective dose of guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof. An alternative method involves contacting the bacterial pathogen with guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: November 14, 2023
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Mohammad R. Seyedsayamdost, Bethany K. Okada, Anran Li
  • Patent number: 11753365
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: September 12, 2023
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 11737986
    Abstract: Thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: August 29, 2023
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Shivaji Phadke, Vaishnavi Parikh
  • Patent number: 11712420
    Abstract: Thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: August 1, 2023
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Shivaji Phadke, Vaishnavi Parikh
  • Patent number: 11707443
    Abstract: The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: July 25, 2023
    Assignee: RK PHARMA INC.
    Inventors: Kannan Essakimuthu Muthaiyyan, Debjani Manoj Singh, Nirav Ishwarlal Khatri, Sushrut Krishnaji Kulkarni, Alex Kochukunju George, Sushilkumar Dhanaji Patil, Jay Shantilal Kothari
  • Patent number: 11696905
    Abstract: Ready-to-use, stable aqueous intravenous tranexamic acid compositions are provided.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: July 11, 2023
    Assignee: RTU Pharma SA
    Inventors: Thomas Jacobsen, Eric Dubois
  • Patent number: 11696903
    Abstract: Compounds and methods of scavenging bifunctional electrophiles and reducing the occurrence of lysyl-levuglandin adducts in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: July 11, 2023
    Assignees: Vanderbilt University, The United States as Represented by the Department of Veterans Affairs
    Inventors: Keith T. Wilson, John A. Oates, Olivier Boutaud, Venkataraman Amarnath, Erica J. Carrier, Alain P. Gobert
  • Patent number: 11685847
    Abstract: Adhesives for use on user-to-mask interfaces of a respiratory mask and methods of preparing the same are provided. The adhesive includes greater than or equal to about 1 wt. % to less than or equal to about 15 wt. % of one or more glycerides; greater than or equal to about 0.50 wt. % to less than or equal to about 5 wt. % of one or more polyacrylates; greater than or equal to about 1 wt. % to less than or equal to about 10 wt. % of one or more polyethers; greater than or equal to about 25 wt. % to less than or equal to about 45 wt. % of one or more N-vinylpyrrolidone polymers; and a balance of water. The method includes forming a first aqueous mixture, forming a second aqueous mixture, and admixing the first aqueous mixture and the second aqueous mixture to form a substantially homogeneous mixture that defines the adhesive.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: June 27, 2023
    Assignee: Seal Solutions, Inc.
    Inventors: Sandra Jensen, Kathryn Weiher
  • Patent number: 11678682
    Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: June 20, 2023
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, Jr.
  • Patent number: 11633353
    Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 25, 2023
    Assignee: DIZLIN PHARMACEUTICALS AB
    Inventors: Elias Eriksson, Nil Dizdar Segrell, Mats Ehrnebo, Leif Bring
  • Patent number: 11590095
    Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: February 28, 2023
    Assignee: BANNER LIFE SCIENCES LLC
    Inventors: Jason M. Vaughn, Justin R. Hughey, Tanesha Roberts, Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
  • Patent number: 11535538
    Abstract: Formulation F comprising A) 50 to 90 parts by weight of at least one block copolymer P of ethyleneoxide and propylene oxide, B) 0.5 to 10 parts by weight of at least one salt of an alkyl sulfate S, C) 0.05 to 0.5 parts by weight of a composition C comprising C1) 5 to 10 parts by weight of at least one polydimethylsiloxane bearing only terminal alkyl groups, C2) 1 to 3 parts by weight of at least one polydimethylsiloxane bearing at least alkoxylated hydroxy group, C3) at least one solvent, wherein said formulation F is an aqueous formulation.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: December 27, 2022
    Assignee: Solenis Technologies, L.P.
    Inventors: Stephan Nied, Helena Kondardi, Lisa Marie Winzen
  • Patent number: 11523984
    Abstract: Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 13, 2022
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, John Devane, Sharon Hamm, David Penake
  • Patent number: 11497766
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: November 15, 2022
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 11491125
    Abstract: Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: November 8, 2022
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, David Penake
  • Patent number: 11446268
    Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 20, 2022
    Assignee: YAMO PHARMACEUTICALS LLC
    Inventors: Steven Hoffman, John Rothman
  • Patent number: 11426361
    Abstract: A method for treatment of irritation or damage to corneal or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, comprising applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: August 30, 2022
    Assignee: Resdevco Research and Development Co. Ltd.
    Inventor: Shabtay Dikstein
  • Patent number: 11324696
    Abstract: Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 10, 2022
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Ken Fallin, Zeus Pendon, Priya Capila, Neal Muni
  • Patent number: 11291701
    Abstract: The present invention is related to an orally disintegrating, sublingual or buccal formulation of active ingredient such as cannabidiol or tetrahydrocannabinol.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 5, 2022
    Assignee: SEED EDIBLES
    Inventor: Danny S. Gonzalez
  • Patent number: 11273129
    Abstract: An object of the present invention is to provide a particulate composition for an easy-to-take solid preparation, which has excellent moldability (hardness) and slipperiness. The present invention relates to a particulate composition for an easy-to-take solid preparation, comprising sugar alcohol and a gelling agent that will show slipperiness when it is brought into contact with water, wherein a part or whole of the surface of the particulate composition is coated with the gelling agent, to an easy-to-take solid preparation comprising the particulate composition, and to a method for the production of the easy-to-take solid preparation.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: March 15, 2022
    Assignee: DAICEL CORPORATION
    Inventors: Momoko Hamasaki, Tomohito Okabayashi, Anan Sakaguchi, Takahiro Hiramura
  • Patent number: 11110073
    Abstract: The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 7, 2021
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Sushilkumar Dhanaji Patil, Nirav Ishwarlal Khatri, Alex Kochukunju George, Sushrut Krishnaji Kulkarni
  • Patent number: 11096915
    Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 24, 2021
    Assignee: EMP Levo US B.V.
    Inventors: Yannis Psarrakis, Konstantinos Lioumis
  • Patent number: 11096913
    Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 24, 2021
    Assignee: ALTERGON SA
    Inventors: Tiziano Fossati, Lorenzo Bellorini, Marco Pizzutti
  • Patent number: 11033513
    Abstract: A method for treatment of irritation or damage to conical or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, by applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: June 15, 2021
    Assignee: Resdevco Research and Development Co. Ltd.
    Inventor: Shabtay Dikstein
  • Patent number: 11000523
    Abstract: The present disclosure relates to a new pharmaceutical composition comprising Ceritinib. Particularly it is directed to the tablet that is prepared by wet granulation, wherein povidone is used as a binder. Further feature of the composition is that the drug and the binder form the inner phase, whereas all other excipients are added in a powder form as an outer phase. This way, the sticking of the composition is prevented and sufficient tablet hardness can be reached.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: May 11, 2021
    Inventors: Sebastien Breulles, Simon Ensslin
  • Patent number: 11000495
    Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium in high amounts, and methods for their use. Said compositions represent emulsion-gels as well as gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and effective pain relief. The invention also provides methods for treating pain or inflammation in a mammalian subject in need thereof, including acute and chronic pain or inflammation; and kits therefor.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 11, 2021
    Assignee: GSK Consumer Healthcare S.A.
    Inventors: Gregory Johnson, Eric Woodward
  • Patent number: 10980757
    Abstract: Ready-to-use, stable aqueous intravenous tranexamic acid compositions are provided.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 20, 2021
    Assignee: RTU Pharma SA
    Inventors: Thomas Jacobsen, Eric Dubois
  • Patent number: 10933042
    Abstract: An intravenous baclofen solution is disclosed, along with methods of dosing and treatment therewith.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 2, 2021
    Assignees: Allaysis, LLC, Regents of the University of Minnesota
    Inventors: James C. Cloyd, Adolfo L. Gomez, Linda Krach, Robert L. Kriel, John Schrogie, Stephen John Tucker, Rob Tuohy
  • Patent number: 10836708
    Abstract: Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical compositions containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 17, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Richard B. Silverman, Matthew Moschitto
  • Patent number: 10751303
    Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 25, 2020
    Assignee: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.
    Inventor: Paul G. Ambrose
  • Patent number: 10729716
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: August 4, 2020
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 10624839
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: April 21, 2020
    Assignee: NeuroDerm, Ltd.
    Inventor: Oron Yacoby-Zeevi
  • Patent number: 10537538
    Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 21, 2020
    Assignee: Altergon SA
    Inventors: Tiziano Fossati, Lorenzo Bellorini, Marco Pizzutti
  • Patent number: 10441573
    Abstract: The present invention relates to the use of DBH inhibitors (e.g., disulfiram and Nepicastat), and pharmaceutical compositions thereof, for treating subjects with certain types of memory loss, for instance memory loss associated with a neurodegenerative disease, disorder, or condition, such as Alzheimer's Disease.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 15, 2019
    Assignee: Brandeis University
    Inventor: John Lisman
  • Patent number: 10426836
    Abstract: The present inventions relate generally to compositions, kits, and methods for the treatment of stress-related disorders, including but not limited to post-traumatic stress disorder.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 1, 2019
    Assignee: Hoffman Technologies, Inc.
    Inventor: Steven Hoffman
  • Patent number: 10377698
    Abstract: Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurodegenerative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e.g. esters, ethers, amides), processes for their preparation and their application in the manufacture of pharmaceutical products.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 13, 2019
    Assignee: University of Innsbruck
    Inventors: Helmut Schmidhammer, Mariana Spetea, Elena Guerrieri
  • Patent number: 10307404
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 4, 2019
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10258585
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 16, 2019
    Assignee: NeuroDerm, Ltd.
    Inventor: Oron Yacoby-Zeevi
  • Patent number: 10092549
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10028927
    Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: July 24, 2018
    Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITED
    Inventor: Adrian Davis
  • Patent number: 9782376
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: October 10, 2017
    Assignee: Fresenius Kabi USA LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • Patent number: 9707197
    Abstract: The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 18, 2017
    Assignee: Multimode Medical Inc.
    Inventor: Patrick Musitano
  • Patent number: 9682923
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: June 20, 2017
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 9636316
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: May 2, 2017
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 9622996
    Abstract: A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: April 18, 2017
    Inventors: Shuguang Lin, Meng Zheng
  • Patent number: 9610269
    Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: April 4, 2017
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala
  • Patent number: 9579385
    Abstract: Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: February 28, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Chetan P. Pujara, Richard S. Graham, Melissa Gulmezian, Kristin Prinn, Ramakrishnan Srikumar
  • Patent number: 9561277
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 7, 2017
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Shirou Sawa, Shuhei Fujita